Ask AI
Rationale for TROP2 ADCs in TNBC

CME

Foundations of ADC Therapy and the Clinical Rationale for Targeting TROP-2 in TNBC

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: July 10, 2026

Expiration: January 09, 2027

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Ana C. Garrido-Castro, MD, discusses why TROP-2 is a clinically relevant ADC target in metastatic TNBC, how ADC design features influence efficacy and toxicity, and how multidisciplinary planning can support safe integration of these therapies in practice.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with breast cancer do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

In patients with TNBC, which statement best reflects the current understanding of TROP-2 expression and its relationship to prognosis?